13th week of 2015 patent applcation highlights part 41 |
Patent application number | Title | Published |
20150086506 | ALTERATION OF CELL MEMBRANE FOR NEW FUNCTIONS - Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis. | 2015-03-26 |
20150086507 | Bruton's Tyrosine Kinase Inhibitors for Hematopoietic Mobilzation - Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed. | 2015-03-26 |
20150086508 | COMPOSITIONS AND METHODS FOR ENHANCING EPIDERMAL REPAIR AND CUTANEOUS INNATE IMMUNITY - The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNFα and OSM that can be formulated for topical administration for cosmetic or dermatologic use. | 2015-03-26 |
20150086509 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING INTERFERON AND MAPK PATHWAY INHIBITOR - The present invention provides for methods and compositions for treating cancer. A subject having cancer is administered an interferon and an inhibitor of mitogen-activated protein kinase (MAPK) signaling pathway. The combination of the interferon and the inhibitor of the MAPK pathway produces a synergistic effect on the cancer compared to the effect of the interferon or the inhibitor of the MAPK pathway alone. The activity of the interferon pathway, interferon expression levels and/or interferon locus copy number can be used as biomarkers for treatment of cancer by MAPK pathway inhibitors. | 2015-03-26 |
20150086510 | S100 FAMILY PROTEINS AND THEIR USES - The present invention relates to S100 family proteins and their uses. Moreover, the present invention relates to pharmaceutical compositions comprising an S100 family protein. | 2015-03-26 |
20150086511 | SURVIVAL, DIFFERENTIATION AND STRUCTURAL INTEGRATION OF HUMAN NEURAL STEM CELLS GRAFTED INTO THE ADULT RAT SPINAL CORD - The present invention provides methods and compositions for treating spinal cord diseases and injuires. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue. | 2015-03-26 |
20150086512 | METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS - The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases. | 2015-03-26 |
20150086513 | METHOD FOR DERIVING MELANOCYTES FROM THE HAIR FOLLICLE OUTER ROOT SHEATH AND PREPARATION FOR GRAFTING - The present invention relates to the field of biology and medicine, and more specifically, to the field of stem-cell biology, involving producing or generating melanocytes from stem-cells and precursors derived from human hair root. Additionally, the present invention relates to the materials and method for producing autografts, homografts or allografts comprising melanocytes in general, as well as the materials and methods for producing autografts, homografts and allografts comprising melanocytes for the treatment of diseases related to depigmentation of the skin and for the treatment of scars. | 2015-03-26 |
20150086514 | MESENCHYMAL STEM CELL INJECTION AND PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN PREPARING DIABETES DRUG - The present invention provides a mesenchymal stem cell injection, a preparation method thereof, and application thereof in preparing diabetes mellitus drug. Mesenchymal stem cells used by the present invention come from the human umbilical cord and the human placenta. The ingredients of the mesenchymal stem cell injection are: mesenchymal stem cells, human albumin, low molecular weight heparin, a compound amino acid, vitamin C, and a solution medium. The solution medium is a compound electrolyte solution, glucose water, or a normal saline solution. | 2015-03-26 |
20150086515 | IMAGING-AIDED GENE THERAPY USING MESENCHYMAL STEM CELLS AS TARGET-DELIVERY VEHICLE - Compositions and methods of use thereof encompass engineered mesenchymal stem cells as a vehicle to deliver secreted tissue necrosis factor-RGD4C fusion polypeptides for tumor treatment, thereby reducing side effects of TNF. A reporter gene can be included in vector constructs to monitor the localization and viability of engineered MSCs after administration into a recipient animal. The genetically modified mesenchymal stem cell can comprise an expression cassette comprising a nucleic acid sequence operably linked to a gene expression promoter and encoding the heterologous fusion polypeptide comprising a tissue necrotic factor region and an integrin-binding region. Another aspect of the disclosure encompasses embodiments of a method of modulating the proliferation of a targeted population of tumor cells by delivering a population of the genetically modified mesenchymal stem cells to tumor cells, allowing the mesenchymal stem cells to express the heterologous polypeptide, thereby reducing the proliferative capacity of the tumor cells. | 2015-03-26 |
20150086516 | Methods, Compositions, and Devices to Induce Mobilization and Recruitment of Progenitor Cells - Methods, compositions and systems are provided for mobilizing and recruiting progenitor, progenitor-like cells, and/or stem cells to a target site, such as an in vivo site in a patient in need of treatment. In embodiments, the methods include embedding cells in a matrix material having a three-dimensional structure capable of contacting the cells in a non-planar manner to alter the secretome of the cells and/or miRNA expression in a manner effective to recruit progenitor, progenitor-like, or stem cells. | 2015-03-26 |
20150086517 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 2015-03-26 |
20150086518 | METHODS FOR GENERATING PANCREATIC TISSUE - This document provides methods and materials related to tissue generation. For example, methods for generating pancreatic tissue and providing a population of hormone-secreting cells, e.g., insulin-producing cells in a human subject are provided. | 2015-03-26 |
20150086519 | IMPREGNATED ODOUR CONTROL PRODUCTS AND METHODS OF MAKING THE SAME - A product capable of controlling odours arising from organic matter, and a method of making the product. The product comprises an admixture of a moldable thermoplastic and a benign dormant bacteria in a sporulated form, which admixture is formed by mixing the benign dormant bacteria into the moldable thermoplastic when the moldable thermoplastic is melted, and molding the admixture into a molded product. The benign dormant bacteria are embedded throughout the molded product, including being buried within a body of the molded product and being presented on a surface of the molded product. The benign dormant bacteria presented on the surface of the molded product are activatable upon exposure of the surface of the molded product to the organic matter, and the benign activated bacteria digest the organic matter to control production of offensive odours. Abrasive wear of the surface of the molded product exposes fresh benign dormant bacteria buried in the body to the surface for additional odour control. | 2015-03-26 |
20150086520 | Cell Compositions and Methods of Using Same - The present invention provides cell compositions and methods of using treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease. | 2015-03-26 |
20150086521 | Medicament for the Treatment of Acute Myeloid Leukemia (AML) - The present invention relates to the therapeutic treatment of Acute Myeloid Leukemia (AML). It concerns in particular a novel composition for the treatment of this cancer and an associated therapeutic treatment method. The invention concerns a suspension of erythrocytes encapsulating asparaginase as a medicament for treating Acute Myeloid Leukemia (AML). The invention also concerns a method for treating Acute Myeloid Leukemia (AML) comprising administering an efficient amount of a suspension of erythrocytes encapsulating asparaginase. | 2015-03-26 |
20150086522 | Formulation containing herb infused aloe - The present invention provides for a vitamin and herb infused | 2015-03-26 |
20150086523 | Agmatine Containing Dietary Supplements, Nutraceuticals and Foods - The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions. | 2015-03-26 |
20150086524 | OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS - Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously. | 2015-03-26 |
20150086525 | PREBIOTIC COMPOSITION OR PHARMACEUTICAL COMPOSITION SYNTHESIZED FROM CATALYTIC DOMAINS PRODUCING HIGHLY ALPHA-1,2 BRANCHED DEXTRAN - The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same. | 2015-03-26 |
20150086526 | SUBCUTANEOUS ADMINISTRATION OF IDURONATE- 2-SULFATASE - The present invention provides, among other things, compositions, kits and methods for subcutaneous delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention provides methods for treating Hunter syndrome by subcutaneous administration of a replacement iduronate-2-sulfatase (I2S) protein. In some embodiments, the present invention provides a kit comprising an arrangement of components for subcutaneously administering iduronate-2-sulfatase (I2S) protein. | 2015-03-26 |
20150086527 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CORNEAL ENDOTHELIAL WOUNDS CONTAINING ANGIOGENIN - Provided is a pharmaceutical composition for treating corneal endothelium wounds, the composition including angiogenin as an effective ingredient. The present invention relates to a new topical therapeutic use of angiogenin for treatment of corneal endothelium wounds, wherein the angiogenin that is generally known to be involved in angiogenesis activates a PI3K/Akt/eNOS pathway thereof in ocular corneal endothelium to increase migration and proliferation of corneal endothelial cells that are not capable of self-proliferation and to promote prevention and treatment of corneal endothelial cell wounds. | 2015-03-26 |
20150086528 | Compositions and Methods for Enhancing Metal Ion Dependent Drug Therapies - Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers. | 2015-03-26 |
20150086529 | Therapeutic Burn Gel - Therapeutic Radiation Burn Gel is an invention that promotes the healing of radiated skin. It works by softening the layers of necrotic tissue which form (in the skin) post radiation. The softening of the necrotic tissue allows for it to be safely and gently peeled away, in order to promote healing. In addition, the Gel is comprised of natural ingredients: Amylase contained in an Aloe Vera gel base. Amylase is an enzyme which is a component of normal human saliva. It softens radiated tissue by way of its lysing action on the sugars and starches which occur naturally in human skin. | 2015-03-26 |
20150086530 | DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE - The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin and enzyme replacement therapy for the treatment of Pompe disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin hydrochloride and alglucosidase alfa for the treatment of Pompe disease. | 2015-03-26 |
20150086531 | METHODS FOR MODIFYING PROGRESSION OF OSTEOARTHRITIS - Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein. | 2015-03-26 |
20150086532 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating major depression comprising the steps of: identifying a subject with one or more symptoms of a depressive disorder; and administering a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of depression. | 2015-03-26 |
20150086533 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating anxiety disorder comprising the steps of: identifying a subject with one or more symptoms of an anxiety disorder; a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of anxiety disorder. | 2015-03-26 |
20150086534 | METHODS OF USE OF SECRETORY IgA - Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA. | 2015-03-26 |
20150086535 | Use of Survivin Antagonists in Polyomavirus-Related Disease - A method of treating a polyomavirus (+) cancer in which survivin is upregulated in a patient is provided, comprising administering to the patient a therapeutically effective amount of a composition that downregulates survivin expression or function in cells of the polyomavirus (+) cancer. A method of reducing growth of polyomavirus (+) cancer cells in which survivin is up-regulated is provided, comprising contacting the cells with an amount of a composition that downregulates survivin expression or function effective to reduce growth of the cells. Also provided is sepantronium salt, for use in treating a polyomavirus (+) cancer in which survivin is up-regulated. | 2015-03-26 |
20150086536 | Methods of Predicting Acute Rejection Outcomes - A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ. | 2015-03-26 |
20150086537 | HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 2015-03-26 |
20150086538 | ANTIBODY LIGHT CHAINS - The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors. | 2015-03-26 |
20150086539 | CROSS-REACTIVE STAPHYLOCOCCUS AUREUS ANTIBODY - The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of | 2015-03-26 |
20150086540 | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling - The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases. | 2015-03-26 |
20150086541 | Methods of Cytotoxic Gene Therapy To Treat Tumors - A method is disclosed for decreasing or retarding an increase in the size of a localized or metastatic tumor by using a combination of an immune stimulating cytotoxic gene therapy and immune-checkpoint modulating agent, in conjunction with other therapies, including radiation therapy, chemotherapy, surgery, and immunotherapies. | 2015-03-26 |
20150086542 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF MICROBIAL INFECTIONS - This disclosure provides methods and compositions to inhibit or prevent infection of a cell by a bacteria that exports DNABII proteins by administering to a tissue infected with the bacteria an effective amount of an antibody that specifically recognizes and binds the DNABII proteins, thereby inhibiting or preventing infection of the bacteria. Treatment methods, screens and kits are further provided. | 2015-03-26 |
20150086543 | DIAGNOTIC MARKERS - The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene. | 2015-03-26 |
20150086544 | STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS - The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention. | 2015-03-26 |
20150086545 | COMBINATION THERAPY OF HER EXPRESSING TUMORS - The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors. | 2015-03-26 |
20150086546 | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 2015-03-26 |
20150086547 | COMBINATION THERAPY FOR TREATING BREAST CANCER - The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer. | 2015-03-26 |
20150086548 | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions - Embodiments of the present invention relate to compositions and methods of treating type 1 or type 2 diabetes mellitus or other conditions relating to metabolic dysfunction that may impact insulin secretion or action by administering an islet neogenesis agent in combination with an agent or agents that selectively inhibits, blocks or destroys the autoimmune destruction of pancreatic cells or agents that optimize function within existing islets in patients with type 1 diabetes, type 2 diabetes and related conditions. | 2015-03-26 |
20150086549 | TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis. | 2015-03-26 |
20150086550 | COMBINATION OF THE APPLICATION OF ANTIBODIES FOR IMMUNOSTIMULATION TOGETHER WITH GLUCOCORTICOIDS - The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid. | 2015-03-26 |
20150086551 | Novel Therapeutic Agents - The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases. | 2015-03-26 |
20150086552 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 2015-03-26 |
20150086553 | POLYPEPTIDE BINDING TO ANNEXIN A1 AND USE THEREOF - A polypeptide binding to Annexin A1, an antagonist against Annexin A1 including the polypeptide, an anti-Annexin A1 antibody including the polypeptide or an antigen-binding fragment thereof, and methods of preventing, treating and/or diagnosing a disease, including administering the antagonist and/or the antibody or an antigen-binding fragment thereof to a subject. | 2015-03-26 |
20150086554 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 2015-03-26 |
20150086555 | Anti-Hemagglutinin Antibody Compositions and Methods of Use Thereof - The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection. | 2015-03-26 |
20150086556 | Anti-Activin A Antibodies and Uses Thereof - The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases. | 2015-03-26 |
20150086557 | NOVEL INTEGRIN alpha9 beta1 LIGAND AND USES THEREOF - Provided is a novel ligand for integrin α9β1 consisting of a peptide having the following amino acid sequence:
| 2015-03-26 |
20150086558 | ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CEMX DOMAINS - Antibodies binding to junction regions between the CH4 and CεmX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases. | 2015-03-26 |
20150086559 | ANTIBODY FORMULATION - Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid. | 2015-03-26 |
20150086560 | INFLUENZA VACCINE AND THERAPY - The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response. | 2015-03-26 |
20150086561 | BINDING MOIETIES FOR BIOFILM REMEDIATION - Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described. | 2015-03-26 |
20150086562 | ANTI-CD22 ANTIBODIES - Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof including therapeutic compositions, methods and devices. | 2015-03-26 |
20150086563 | ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY - There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them. | 2015-03-26 |
20150086564 | NOVEL ANTIBODIES ANTI-sPLA2-IIA AND USES THEREOF - The present invention relates to antibodies anti-sPLA2-IIA and uses thereof. | 2015-03-26 |
20150086565 | CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS - Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients. | 2015-03-26 |
20150086566 | Stabilised protein solutions - The invention relates to a method of stabilizing highly concentrated protein solutions during ultrafiltration by addition of sucrose to the highly concentrated protein solution, in particular, but not exclusively to a method of stabilizing highly concentrated antibody solutions during ultrafiltration by addition of sucrose to the highly concentrated antibody solution. | 2015-03-26 |
20150086567 | ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE - The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis. | 2015-03-26 |
20150086568 | ANTI-VEGF ANTIBODIES - The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies. | 2015-03-26 |
20150086569 | Use of TNFalpha Inhibitor for Treatment of Erosive Polyarthritis - The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. | 2015-03-26 |
20150086570 | BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS - The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with αvβ6 integrin inhibition or therapy with TGF-β pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against αvβ6-integrin and/or TGF-β pathway inhibitors. | 2015-03-26 |
20150086571 | METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST - The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug. | 2015-03-26 |
20150086572 | Complement Pathway Inhibitors Binding To C5 And C5A Without Preventing The Formation Of C5B - The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a. | 2015-03-26 |
20150086573 | BIRTH TISSUE MATERIAL AND METHOD OF PREPARATION - A placental construct for treatment of a disease or condition is provided. The placental construct includes a therapeutically effective amount of a birth tissue material. | 2015-03-26 |
20150086574 | ANTIBODIES THAT SPECIFICALLY BIND TO TIM3 - Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation. | 2015-03-26 |
20150086575 | B CELL SURFACE REACTIVE ANTIBODIES - The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL. | 2015-03-26 |
20150086576 | SORTASE-MODIFIED VHH DOMAINS AND USES THEREOF - In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided. | 2015-03-26 |
20150086577 | PATHOGENIC PHLEBOVIRUS ISOLATES AND COMPOSITIONS AND METHODS OF USE - Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject. | 2015-03-26 |
20150086578 | HUMAN CYTOMEGALOVIRUS VACCINE - Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 and UL131 components of the gH/gL/UL128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of UL130 and amino acid residues 90-106 of UL131. The combination peptides, polypeptides and proteins, and the nucleic acids encoding them, may be used in vaccines, and as diagnostic and research tools. | 2015-03-26 |
20150086579 | ADENOVIRAL-BASED VECTORS - The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype. | 2015-03-26 |
20150086580 | RATIONAL VACCINE DESIGN FOR HEPATITIS C VIRUS - Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response. | 2015-03-26 |
20150086581 | Fast Diagnosis and Personalized Treatment for Acne - Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof. | 2015-03-26 |
20150086582 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2015-03-26 |
20150086583 | MUCIN-ASSOCIATED SURFACE PROTEIN AS VACCINE AGAINST CHAGAS DISEASE - Use of synthetic peptides derived from | 2015-03-26 |
20150086584 | MULTI-SPECIFIC BINDING AGENTS - Compositions comprising aptamers or other binding ligands provide immune cell regulatory signals and specificity to secreted cell molecules at in vivo foci of immune activity. | 2015-03-26 |
20150086585 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF - The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation. | 2015-03-26 |
20150086586 | ACELLULAR PERTUSSIS VACCINE - Described are acellular pertussis (aP) vaccine compositions comprising | 2015-03-26 |
20150086587 | VACCINE ADJUVANT - Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil. The adjuvant emulsions can be used to potentiate the immunological effects of active agents, including antigens derived from various pathogens and/or toxins. Immunogenic compositions comprising the adjuvant emulsions and various active agents are also provided, along with vaccine systems for therapeutic or prophylactic treatment of a subject using these adjuvants. | 2015-03-26 |
20150086588 | PARAINFLUENZA VIRUS 5 BASED VACCINES - The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (HN) gene and the large RNA polymerase protein (L) gene of the PIV5 genome. In some embodiments, the heterologous nucleotide sequence is inserted between the small hydrophobic protein (SH) gene and the hemagglutinin-neuroaminidase (HN) gene of the PIV 5 genome. | 2015-03-26 |
20150086589 | VIRUS-LIKE PARTICLES COMPRISING A MATRIX PROTEIN FROM A PLANT ENVELOPED VIRUS AND USES THEREOF - The present invention relates to novel virus-like particles (VLPs) comprising a matrix protein derived from a first plant enveloped virus and a surface polypeptide. The surface polypeptide comprises (a) a surface exposed portion derived from a target polypeptide (b) a transmembrane domain, and (c) a cytosolic tail derived from a transmembrane (e.g., glycoprotein) of a second plant enveloped virus. The target polypeptide may be antigenic or therapeutic. The first and the second plant enveloped viruses may be the same. Either plant enveloped virus may be a plant rhabdovirus. Also provided are methods of making and using the VLPs. | 2015-03-26 |
20150086590 | LPS VACCINE - A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith. | 2015-03-26 |
20150086593 | Allergy Inhibitor Compositions And Kits And Methods Of Using The Same - Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a | 2015-03-26 |
20150086594 | ANTI-ALLERGIC MEDICAMENT - The present disclosure relates to a method for the treatment of allergic conditions. In said method the allergens to which an individual is susceptible is identified as per the allergy profile and accordingly a formulation having potentized dispersions of each of the identified allergens is administered to the individual for a predetermined period and at a predetermined potency. The present disclosure also relates to a formulation which is a mixture of potentized dispersions of each of the identified allergens and the method of preparation for the same. The present disclosure further relates to a kit consisting of at least one allergen, at least one vehicle and accessories which include bottles and mixing sticks. | 2015-03-26 |
20150086595 | Spray Drying Microcapsules - Spray drying microcapsules with particulates, the microcapsules that result from such spray drying, and compositions and methods of making said compositions including the spray-dried microcapsules. | 2015-03-26 |
20150086596 | ORGANOPHOSPHATES FOR TREATING AFFLICTIONS OF THE SKIN - Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of | 2015-03-26 |
20150086597 | ANTIMICROBIAL COPPER OR COPPER ALLOY PRODUCTS AND METHOD FOR MANUFACTURING SAME - A copper or copper alloy product is provided, as well as a process for manufacturing a copper or copper alloy product. The product may include copper or copper alloy containing a minimum of 60% copper. The product may include an antimicrobial copper, such as, for example, the antimicrobial copper identified by the United States Environmental Protection Agency (EPA). The product may include, but is not limited to, for example, MD-Cu | 2015-03-26 |
20150086598 | PROCESS OF MAKING ANTIBACTERIAL COATING AND ANTIBACTERIAL PAPER WITH SAME, AND ANTIBACTERIAL PAPER - An antibacterial paper comprises a paper substrate, wherein at least one external surface of the paper substrate is coated with an antibacterial coating layer containing titanium dioxide particles uniformly distributed therein, the average particle size of the titanium dioxide particles is less than or equal to 200 nanometers (nm), and the mass percentage of the titanium dioxide particles contained in the antibacterial coating layer is more than or equal to 5% of the mass of the antibacterial coating layer. | 2015-03-26 |
20150086599 | Self Assembled Films for Protein and Drug Delivery Applications - Provided are systems for controlled release of proteins from decomposable thin films constructed by layer-by-layer deposition. Such films generally comprise alternating layers of polymers and proteins, and may further comprise additional layers of polyions. In some embodiments, decomposable thin films and methods of using such films allow proteins to be released over an extended period of time and/or retention of as much as 100% of function of released protein. | 2015-03-26 |
20150086600 | RE-ESTABLISHMENT OF BLOOD FLOW IN BLOCKED HUMAN ARTERIES BY TRANSFERRING NANO-ENCAPSULATED DRUG THROUGH MEDICAL DEVICES, DESIGNED FOR THE SAME AND RELEASING THE NANO-ENCAPSULATED DRUG IN HUMAN ARTERY WITH BODY PH - A drug-delivering insertable medical device for treating a medical condition associated with a body lumen is disclosed. The drug-delivering insertable medical device includes an outer surface coated with two or more nano-carriers having two or more average diameters. A nano-carrier of the two or more nano-carriers has an average diameter suitable for penetrating one or more layers of two or more layers of the body lumen. The nano-carrier includes a drug surrounded by an encapsulating medium. The encapsulating medium includes one or more of a biological agent, a blood excipient, and a phospholipid. | 2015-03-26 |
20150086601 | METHODS FOR PREVENTING BIOFILM FORMATION - Provided are methods for the treatment or prevention of microbial infections (e.g., nocosomial infection) in which the underlying pathology involves a PNAG-containing microbial bio film. The methods the invention generally involve administering to the subject an effective amount of an antibody that specifically binds to PNAG and disrupt or inhibit formation of PNAG-containing microbial bio films. Such methods are particularly useful for the treatment of nosocomial | 2015-03-26 |
20150086602 | METHODS FOR COATING BONE ALLOGRAFTS WITH PERIOSTEUM-MIMETIC TISSUE ENGINEERING SCAFFOLDS - Methods of coating bone surfaces and coated bones comprising a coating comprising (a) a porous polysaccharide scaffold and/or a plurality of polysaccharide nanofibers; and (b) a polyelectrolyte multilayer composition, are disclosed. The methods of coating bone surfaces and the coated bones disclosed provide a biomimetic periosteum to compensate for periosteum lost in preparing bone grafts, and the coated bone grafts, including allografts, restore lost osteogenic and osteoinductive qualities and improve clinical outcomes. | 2015-03-26 |
20150086603 | DUAL-TARGETED DRUG CARRIERS - The present invention relates to implantable medical devices containing surface-treated, dual-targeted drug carriers for treating vascular diseases. | 2015-03-26 |
20150086604 | Mesh Pouches for Implantable Medical Devices - Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The pouches of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use, and, optionally, include one or more drugs in the polymer matrix of the coating to provide prophylactic effects and/or alleviate side effects or complications associated with the surgery or implantation of the CRM or other implantable medical device. | 2015-03-26 |
20150086605 | MULTI-LAYER BIOMATERIAL FOR TISSUE REGENERATION AND WOUND HEALING - The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects. | 2015-03-26 |
20150086606 | BIORESORBABLE AND BIOACTIVE THREE-DIMENSIONAL POROUS MATERIAL AND METHOD FOR THE PRODUCTION THEREOF - A bioresorbable and bioactive three-dimensional porous material made from bioresorbable polymers that can be combined with bioactive ceramics, producing a three-dimensional structure of interlinked pores containing additives capable of allowing the regeneration and formation of tissues, and a method for the production thereof is described. | 2015-03-26 |
20150086607 | FIBER SCAFFOLDS FOR USE CREATING IMPLANTABLE STRUCTURES - A synthetic construct suitable for implantation into a biological organism that includes at least one polymer scaffold; wherein the at least one polymer scaffold includes at least one layer of polymer fibers that have been deposited by electrospinning; wherein the orientation of the fibers in the at least one polymer scaffold relative to one another is generally parallel, random, or both; and wherein the at least one polymer scaffold has been adapted to function as at least one of a substantially two-dimensional implantable structure and a substantially three-dimensional implantable tubular structure. | 2015-03-26 |